Friday, October 25, 2019 Daily Archives

Skids and resins: Pall divulges more on Sartorius divestment

by

In a letter to customers, Pall Corporation has revealed the exact businesses and products it is selling to Sartorius to facilitate Danaher’s acquisition of GE Biopharma. Last week, Danaher Corporation announced plans to divest parts of its bioprocessing businesses to help facilitate the $21.4 billion (€19.2 billion) takeover of GE Healthcare’s Life Sciences business. The firm said rival bioprocess vendor Sartorius is in line to pick up its biomolecular characterization business FortéBio, its SoloHill microcarrier technology unit, and various chromatography…

October 25, 2019

Gene therapy demand drives Cytovance pDNA expansion

by

Cytovance Biologics has added plasmid DNA (pDNA) production capacity at its Oklahoma City facility citing growing demand from gene therapy developers. The single-use production system is capable of making both critical reagent grade – for research – and cGMP grade pDNA in quantities ranging from 1g to 50g. It can manufacture smaller quantities for R&D. Jesse McCool, Cytovance chief technology officer (CTO), framed the investment as part of the firm’s effort to position itself as a key gene therapy supply…

October 25, 2019

Zolgensma: Manufacturing questions delay decision in EU and Japan

by

Novartis has asked the EMA to inspect its Zolgensma plant in San DIego after the agency – and Japan’s PDMA – delayed approval decisions and asked for more details of how the gene therapy is made. Zolgensma is a gene therapy. It is designed to halt progressive spinal muscular atrophy (SMA) – motor neurone loss and muscle wasting – in kids with a defective version of a gene called SMN1. The drug encodes a functional copy of the gene enabling sustained…

October 25, 2019

Biogen’s services revenues fall; Aducanumab re-emerges

by

Biogen saw its manufacturing services revenue slide in Q3 following the sale of its plant in Hillerod, Denmark. According to Biogen’s Q3 report the firm’s “other revenues†–those not generated by drug product sales – fell 26% year on year to $110m. CFO Jeff Capello attributed the decline to the divestiture of the firm’s biologics manufacturing in Hillerod facility to Fujifilm. “Total other revenues in the third quarter decreased 26% versus the prior year driven by the decline in our…

October 25, 2019